Alignment Healthcare, Inc. (NASDAQ:ALHC – Get Free Report) insider Andreas Wagner sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $17.84, for a total transaction of $214,080.00. Following the transaction, the insider directly owned 160,230 shares in the company, valued at $2,858,503.20. The trade was a 6.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.
Alignment Healthcare Stock Down 1.1%
ALHC stock opened at $17.96 on Friday. The stock has a market capitalization of $3.67 billion, a P/E ratio of -1,794.01, a PEG ratio of 2.66 and a beta of 1.18. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.71 and a current ratio of 1.71. Alignment Healthcare, Inc. has a one year low of $11.63 and a one year high of $23.87. The company has a 50 day moving average price of $20.51 and a two-hundred day moving average price of $18.78.
Alignment Healthcare (NASDAQ:ALHC – Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. Alignment Healthcare had a negative return on equity of 0.49% and a negative net margin of 0.02%.The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same quarter in the prior year, the company posted ($0.16) EPS. The business’s revenue for the quarter was up 44.4% compared to the same quarter last year. As a group, sell-side analysts expect that Alignment Healthcare, Inc. will post -0.69 EPS for the current year.
Institutional Investors Weigh In On Alignment Healthcare
Key Stories Impacting Alignment Healthcare
Here are the key news stories impacting Alignment Healthcare this week:
- Positive Sentiment: Analyst optimism — several brokerages have raised price targets and maintained Overweight/Buy views (Piper Sandler, KeyCorp, JPMorgan, Robert W. Baird), supporting upside expectations and a consensus “Moderate Buy” rating. MarketBeat ALHC Analyst Coverage
- Positive Sentiment: Recent earnings beat — Alignment reported Q4 revenue of ~$1.01B and EPS of ($0.05), topping consensus (revenue ~ $1.00B; EPS -$0.15), showing strong revenue growth (Y/Y +44%). This fundamental print remains supportive. Earnings Summary
- Neutral Sentiment: Zacks comparison piece — a valuation/comparison article contrasts ALHC with BrightSpring (BTSG); useful context for long-term investors but not an immediate market catalyst. BTSG or ALHC: Which Is the Better Value Stock Right Now?
- Neutral Sentiment: Reported short-interest data appears erroneous (shows 0 shares / NaN changes). Do not treat published short-interest figures as evidence of rising short pressure until exchanges correct the data.
- Negative Sentiment: CEO sale — John E. Kao sold 73,046 shares at an average $17.84 (~$1.30M), trimming his stake ~3.93%. This large insider sale is a near-term negative signal for sentiment. SEC Filing — Kao
- Negative Sentiment: Multiple senior insider sales on Mar 18 — President Dawn C. Maroney (36,749 shares, $17.84; also several prior sales in March/Jan), COO Sebastian Burzacchi (15,361 shares, $17.84), Christopher J. Joyce (25,125 shares, $17.84), Hyong Kim (18,404 shares, $17.84), Andreas P. Wagner (12,000 @ $17.84 and 11,602 @ $18.22), and Robert L. Scavo (11,285 shares, $17.84). These clustered disposals by senior management create headline risk and downward pressure. Representative filings: Maroney — Maroney SEC Filing; Joyce — Joyce SEC Filing; Wagner filings — Wagner SEC Filing
Analysts Set New Price Targets
Several analysts have commented on ALHC shares. Robert W. Baird set a $28.00 price target on Alignment Healthcare in a report on Friday, January 30th. JPMorgan Chase & Co. boosted their target price on shares of Alignment Healthcare from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alignment Healthcare in a research note on Wednesday, January 21st. Wall Street Zen cut shares of Alignment Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, UBS Group increased their target price on Alignment Healthcare from $18.00 to $21.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 14th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Alignment Healthcare has an average rating of “Moderate Buy” and a consensus price target of $24.56.
View Our Latest Stock Report on Alignment Healthcare
About Alignment Healthcare
Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.
At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.
See Also
Receive News & Ratings for Alignment Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alignment Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
